Regeneron: FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
Sanofi (SNY Quick QuoteSNY - Free Report) and partner Regeneron (REGN Quick QuoteREGN - Free Report) announced that the FDA has accepted their resubmitted supplemental biologics license application
Read full article »
President & CEO
Leonard S. Schleifer
Regeneron is a New York-based biotechnology company that researches, develops, and commercializes novel therapeutics for the treatment of inflammatory and infectious diseases.
Read more